Research ExplorerPublicationsMarked heterogeneity of ERG expression in large primary pros...

Marked heterogeneity of ERG expression in large primary prostate cancers.

Standard

Marked heterogeneity of ERG expression in large primary prostate cancers. / Minner, Sarah; Gärtner, Michael; Freudenthaler, Fabian; Bauer, Melanie; Kluth, Martina; Salomon, Georg; Heinzer, Hans; Graefen, Markus; Bokemeyer, Carsten; Simon, Ronald; Sauter, Guido; Schlomm, Thorsten; Wilczak, Waldemar.

In: MODERN PATHOL, Vol. 26, No. 1, 1, 2013, p. 106-116.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Minner, S, Gärtner, M, Freudenthaler, F, Bauer, M, Kluth, M, Salomon, G, Heinzer, H, Graefen, M, Bokemeyer, C, Simon, R, Sauter, G, Schlomm, T & Wilczak, W 2013, 'Marked heterogeneity of ERG expression in large primary prostate cancers.', MODERN PATHOL, vol. 26, no. 1, 1, pp. 106-116. https://doi.org/10.1038/modpathol.2012.130

APA

Minner, S., Gärtner, M., Freudenthaler, F., Bauer, M., Kluth, M., Salomon, G., Heinzer, H., Graefen, M., Bokemeyer, C., Simon, R., Sauter, G., Schlomm, T., & Wilczak, W. (2013). Marked heterogeneity of ERG expression in large primary prostate cancers. MODERN PATHOL, 26(1), 106-116. [1]. https://doi.org/10.1038/modpathol.2012.130

Vancouver

Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G et al. Marked heterogeneity of ERG expression in large primary prostate cancers. MODERN PATHOL. 2013;26(1):106-116. 1. https://doi.org/10.1038/modpathol.2012.130

Bibtex

@article{1627fb5e483d4d1dae479ee68e62475a,
title = "Marked heterogeneity of ERG expression in large primary prostate cancers.",
abstract = "Approximately 50% of prostate cancers are characterized by TMPRSS2 (transmembrane protease serine 2)-ERG (avian v-ets erythroblastosis virus E26 oncogene homolog) gene fusions resulting in an androgen-regulated overexpression of the transcription factor ERG. Some studies have suggested prognostic or predictive relevance of ERG status in prostate cancer. Such concepts could be impaired by extensive ERG heterogeneity in analyzed tumors. The aim of this study was to analyze the extent of heterogeneity for TMPRSS2-ERG fusion in prostate cancer. To enable large-scale studies on the extent of heterogeneity of biomarkers in prostate cancer, a heterogeneity tissue microarray containing samples from 10 different tumor blocks of 190 large prostate cancers selected from a consecutive series of 480 radical prostatectomies was developed. ERG expression was analyzed by immunohistochemistry. Positive ERG immunostaining was found in arrayed cancer-containing samples from 103 of the 178 analyzable patients (58%). ERG immunostaining was homogeneously positive in 29 prostate cancers (16%), whereas heterogeneous ERG positivity was seen in 74 cancers (42%). ERG heterogeneity was within one tumor focus (intrafocal heterogeneity) in 69 cases (93% of heterogeneous cases) and between different tumor foci (interfocal heterogeneity) in 5 cases (7%). Marked intrafocal heterogeneity challenges the concept of TMPRSS2-ERG fusion always representing an early step in prostate cancer development. Marked heterogeneity also compromises the concept of analyzing ERG status for treatment decisions in diagnostic needle core biopsies.",
keywords = "Adult, Aged, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Oncogene Proteins, Fusion, Prostatic Neoplasms, Tissue Array Analysis, Trans-Activators, Tumor Markers, Biological",
author = "Sarah Minner and Michael G{\"a}rtner and Fabian Freudenthaler and Melanie Bauer and Martina Kluth and Georg Salomon and Hans Heinzer and Markus Graefen and Carsten Bokemeyer and Ronald Simon and Guido Sauter and Thorsten Schlomm and Waldemar Wilczak",
year = "2013",
doi = "10.1038/modpathol.2012.130",
language = "English",
volume = "26",
pages = "106--116",
journal = "MODERN PATHOL",
issn = "0893-3952",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Marked heterogeneity of ERG expression in large primary prostate cancers.

AU - Minner, Sarah

AU - Gärtner, Michael

AU - Freudenthaler, Fabian

AU - Bauer, Melanie

AU - Kluth, Martina

AU - Salomon, Georg

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Bokemeyer, Carsten

AU - Simon, Ronald

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Wilczak, Waldemar

PY - 2013

Y1 - 2013

N2 - Approximately 50% of prostate cancers are characterized by TMPRSS2 (transmembrane protease serine 2)-ERG (avian v-ets erythroblastosis virus E26 oncogene homolog) gene fusions resulting in an androgen-regulated overexpression of the transcription factor ERG. Some studies have suggested prognostic or predictive relevance of ERG status in prostate cancer. Such concepts could be impaired by extensive ERG heterogeneity in analyzed tumors. The aim of this study was to analyze the extent of heterogeneity for TMPRSS2-ERG fusion in prostate cancer. To enable large-scale studies on the extent of heterogeneity of biomarkers in prostate cancer, a heterogeneity tissue microarray containing samples from 10 different tumor blocks of 190 large prostate cancers selected from a consecutive series of 480 radical prostatectomies was developed. ERG expression was analyzed by immunohistochemistry. Positive ERG immunostaining was found in arrayed cancer-containing samples from 103 of the 178 analyzable patients (58%). ERG immunostaining was homogeneously positive in 29 prostate cancers (16%), whereas heterogeneous ERG positivity was seen in 74 cancers (42%). ERG heterogeneity was within one tumor focus (intrafocal heterogeneity) in 69 cases (93% of heterogeneous cases) and between different tumor foci (interfocal heterogeneity) in 5 cases (7%). Marked intrafocal heterogeneity challenges the concept of TMPRSS2-ERG fusion always representing an early step in prostate cancer development. Marked heterogeneity also compromises the concept of analyzing ERG status for treatment decisions in diagnostic needle core biopsies.

AB - Approximately 50% of prostate cancers are characterized by TMPRSS2 (transmembrane protease serine 2)-ERG (avian v-ets erythroblastosis virus E26 oncogene homolog) gene fusions resulting in an androgen-regulated overexpression of the transcription factor ERG. Some studies have suggested prognostic or predictive relevance of ERG status in prostate cancer. Such concepts could be impaired by extensive ERG heterogeneity in analyzed tumors. The aim of this study was to analyze the extent of heterogeneity for TMPRSS2-ERG fusion in prostate cancer. To enable large-scale studies on the extent of heterogeneity of biomarkers in prostate cancer, a heterogeneity tissue microarray containing samples from 10 different tumor blocks of 190 large prostate cancers selected from a consecutive series of 480 radical prostatectomies was developed. ERG expression was analyzed by immunohistochemistry. Positive ERG immunostaining was found in arrayed cancer-containing samples from 103 of the 178 analyzable patients (58%). ERG immunostaining was homogeneously positive in 29 prostate cancers (16%), whereas heterogeneous ERG positivity was seen in 74 cancers (42%). ERG heterogeneity was within one tumor focus (intrafocal heterogeneity) in 69 cases (93% of heterogeneous cases) and between different tumor foci (interfocal heterogeneity) in 5 cases (7%). Marked intrafocal heterogeneity challenges the concept of TMPRSS2-ERG fusion always representing an early step in prostate cancer development. Marked heterogeneity also compromises the concept of analyzing ERG status for treatment decisions in diagnostic needle core biopsies.

KW - Adult

KW - Aged

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Oncogene Proteins, Fusion

KW - Prostatic Neoplasms

KW - Tissue Array Analysis

KW - Trans-Activators

KW - Tumor Markers, Biological

U2 - 10.1038/modpathol.2012.130

DO - 10.1038/modpathol.2012.130

M3 - SCORING: Journal article

C2 - 22899295

VL - 26

SP - 106

EP - 116

JO - MODERN PATHOL

JF - MODERN PATHOL

SN - 0893-3952

IS - 1

M1 - 1

ER -